T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

T2 Biosystems reports revenue growth, eyes FDA breakthroughs for expansion

T2 Biosystems demonstrated strong revenue growth and operational improvements in Q3 2024, driven by sepsis test panel sales and strategic partnerships.
While facing financial challenges and regulatory complexities, the company's focus on innovation and market expansion presents significant opportunities for future growth.
Overall, T2 Biosystems remains optimistic about its growth prospects, supported by advancements in its product pipeline and collaborations to combat healthcare challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments

T2 Biosystems Announces Fourth Quarter & Full Year 2021 Financial Results

LEXINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway, Finland, and Türkiye. Under the terms of the agreements, T2 Biosystems will sell T2Dx® Instruments, along with T2Bacteria®, T2Candida® and T2Resistance® Panels through these distributors.

T2 Biosystems Announces Commercial Expansion Through Distributors in Norway, Finland and Türkiye

LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 17, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022

LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO),  a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3.

T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Subvariants

LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021.

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results

LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA).

T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial

LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA).

T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial

LEXINGTON, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO),  a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects the Omicron COVID-19 variant (B.1.1.529).

T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Variant

T2 Biosystems Inc (NASDAQ:TTOO) has executed a territory-exclusive distribution agreement in Taiwan.  Under the agreement terms, T2 Biosystems will sell T2Dx Instruments, along with T2Bacteria, T2Candida, and T2Resistance Panels through this distributor.

T2 Biosystems Shares Are Rising After Exclusive Distribution Pact In Taiwan

LEXINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan.

T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum.

T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Leading rapid diagnostics company to present on critical link between antimicrobial resistance and sepsis treatment outcomes Leading rapid diagnostics company to present on critical link between antimicrobial resistance and sepsis treatment outcomes

T2 Biosystems Participates in the World Anti-Microbial Resistance Congress

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2021 Results - Earnings Call Transcript

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three months ended September 30, 2021.

T2 Biosystems Announces Third Quarter 2021 Financial Results

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021.

T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

T2 Biosystems (NASDAQ:TTOO) is set to give its latest quarterly earnings report on Thursday, 2021-11-04. Here's what investors need to know before the announcement.

Earnings Outlook For T2 Biosystems

T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

T2 Biosystems (TTOO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Grom Social Enterprises

Salem Media Group

Investors are tracking hot penny stocks that are on the move today with a few names getting quite a bit of attention on Friday. The post 3 Hot Penny Stocks for Friday: What's Going on With TTOO, SALM and GROM Today?

3 Hot Penny Stocks for Friday: What's Going on With TTOO, SALM and GROM Today?

LEXINGTON, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2021 after market close on Thursday, November 4, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Third Quarter 2021 Financial Results on November 4, 2021

Expands International Commercialization with Initial Shipment of T2Dx Instruments to Asia Expands International Commercialization with Initial Shipment of T2Dx Instruments to Asia

T2 Biosystems Announces Distribution Agreements in Key Asia-Pacific Markets

LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately.

T2 Biosystems Appoints Laura Adams to Its Board of Directors

Leading rapid diagnostics company shares highlights of comprehensive data presented at AACC, CAP21 and IDWeek Leading rapid diagnostics company shares highlights of comprehensive data presented at AACC, CAP21 and IDWeek

T2 Biosystems Showcases Research from Recent Industry Conferences

Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens

T2 Biosystems Announces BARDA Exercise of Contract Option 2A Valued at $6.4 Million

Leading rapid diagnostics company to share new research at industry conferences throughout Sepsis Awareness Month Leading rapid diagnostics company to share new research at industry conferences throughout Sepsis Awareness Month

T2 Biosystems to Unveil New Data at September Conferences

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

News for T2 Biosystems Stock (TTOO)